As the US continues to undergo policy changes to the pediatric childhood vaccine schedule, clinicians and families are left uncertain on recommendations and guidance. Our roundtable looks to provide some insights and answer questions to some of the more pressing topics around this evolving issue.
03.03.2026 21:11 — 👍 0 🔁 0 💬 0 📌 0
Moderna has cleared a major regulatory milestone in Europe after the EMA’s CHMP recommended approval of mRNA-1083 (mCOMBRIAX), the world’s first combined influenza and COVID-19 vaccine for adults aged 50 and older.
03.03.2026 15:26 — 👍 2 🔁 1 💬 0 📌 0
A modeling analysis shows the potential increases in cases, hospitalizations, deaths, as well as the healthcare costs associated with declining vaccination rates. Patricia Stinchfield, RN, MS, CPNP, discusses the measles outbreaks, strategies to increase vaccination. @nfidvaccines.bsky.social
02.03.2026 21:26 — 👍 0 🔁 2 💬 0 📌 0
Ceftolozane-tazobactam cure rate for multidrug-resistant Pseudomonas aeruginosa infections is higher than with aminoglycosides-polymyxins and comparable to ceftazidime-avibactam. #IDsky #Medsky
02.03.2026 15:40 — 👍 1 🔁 1 💬 0 📌 4
Patricia Stinchfield, RN, MS, CPNP, discusses her medical experience caring for patients with #measles, and what fellow clinicians and the general public should know about less-discussed details and potential complications. @nfidvaccines.bsky.social
02.03.2026 13:49 — 👍 0 🔁 0 💬 0 📌 2
#Breaking The latest CDC numbers show a 15.7% increase of measles cases from week-to-week. This is another large jump in cases, especially from last week where there was a 7.8% increase. The data also shows further outbreak spread across more states.
27.02.2026 16:06 — 👍 0 🔁 0 💬 0 📌 3
Eric Meissner, MD PhD, discusses the takeaways of the ARTISTRY-2, phase 3 study, which compared bictegravir/emtricitabine/tenofovir alafenamide to bictegravir/lenacapavir in adults with HIV who were virologically suppressed. #CROI2026
26.02.2026 20:33 — 👍 0 🔁 0 💬 0 📌 0
Phase 1 data show that the long-acting HIV-1 capsid inhibitor VH-499 is well tolerated as a single intramuscular or subcutaneous injection and demonstrates pharmacokinetics supportive of long-acting dosing intervals. #CROI2026
www.contagionlive.com/view/long-ac...
Dr. Chloe Orkin discusses the takeaways of the ARTISTRY-1 phase 3 study, including its efficacy and safety profile and the potential benefits of a single-tablet regimen in this patient population. #CROI2026
www.contagionlive.com/view/switchi...
New in vitro data presented at CROI show that Atea Pharmaceuticals’ oral nucleotide analog AT-587 demonstrates markedly superior potency against hepatitis E virus compared with existing off-label options, supporting plans to advance the candidate into phase 1 clinical development in 2026. #CROI2026
25.02.2026 14:03 — 👍 1 🔁 0 💬 0 📌 0
Amy Colson MD, MPH, discusses data from the MK8591A-052 trial which showed that switching to doravirine/islatravir maintained durable virologic suppression with efficacy and safety comparable to continuing bictegravir/emtricitabine/tenofovir alafenamide. #CROI2026
24.02.2026 20:13 — 👍 2 🔁 0 💬 0 📌 0
New 96-week sub-group data from the PASO DOBLE study show that adults with virologically suppressed HIV who switched to Dovato experienced significantly lower rates of steatotic liver disease than those who switched to Biktarvy, particularly among individuals with weight gain. #croi2026
24.02.2026 14:24 — 👍 0 🔁 0 💬 0 📌 2
In the phase 3 ARTISTRY-2 trial, switching virologically suppressed people with HIV from B/F/TAF to a once-daily bictegravir/lenacapavir single-tablet regimen maintained viral suppression through Week 48 with comparable safety and tolerability. #CROI2026
www.contagionlive.com/view/novel-s...
In a phase 3 study of virologically suppressed adults with HIV, switching to once-daily doravirine/islatravir (DOR/ISL 100/0.25 mg) maintained high rates of viral suppression through 96 weeks, with no emergent resistance and a favorable safety profile. #CROI2026
www.contagionlive.com/view/switchi...
Traws Pharma announced positive phase 2 results showing its investigational COVID-19 antiviral ratutrelvir as a possible alternative to Paxlovid, including for ineligible patients, while advancing tivoxavir marboxil as a once-monthly oral prophylactic for seasonal influenza.
22.02.2026 14:30 — 👍 2 🔁 1 💬 0 📌 2
This week, read about the changes to the pediatric vaccine schedule, RSV protection, the FDA reversing course on Moderna's influenza vaccine, and more.
www.contagionlive.com/view/top-inf...
The latest CDC numbers show a 7.9% increase of measles cases from week-to-week. While the number of new measles cases are down from the previous week, there are more states and outbreaks circulating throughout the US. #IDtwitter #Medtwitter
www.contagionlive.com/view/measles...
In this month's column, we look at the recommendation changes made by the CDC to the pediatric vaccine schedule, as well as the American Academy of Pediatrics' response with its own vaccine schedule. #IDsky #Medsky
20.02.2026 15:53 — 👍 3 🔁 1 💬 0 📌 1
New phase 3 data show that Merck’s clesrovimab (Enflonsia) maintained a favorable safety profile and supportive pharmacokinetics in high-risk children under 2 years of age during a second RSV season. The company plans to file for expanded regulatory approval. #IDsky #Medsky
19.02.2026 20:38 — 👍 5 🔁 1 💬 0 📌 0
The federal agency is bringing over NIH Director Jayanta "Jay" Bhattacharya, MD, PhD, to fill the position.
19.02.2026 17:04 — 👍 0 🔁 0 💬 0 📌 0
Check out our library of Bench to Bedside Columns from the @sidpharm.bsky.social.
Read columns here: www.contagionlive.com/sap-partner/...
.@invivyd.bsky.social has aligned with the FDA on the design of a phase 3 trial evaluating the safety and immunology of the company's monoclonal antibody, VYD2311, vs mRNA COVID vaccines and in co-administration. #IDsky #Medsky
19.02.2026 13:56 — 👍 0 🔁 0 💬 0 📌 2
New real-world evidence presented by GSK shows its RSV vaccine, Arexvy, was associated with substantial reductions in RSV-related hospitalizations and serious cardiovascular and respiratory complications among older adults. #IDsky #Medsky
18.02.2026 17:51 — 👍 4 🔁 2 💬 0 📌 0
#Breaking After initially refusing to review Moderna’s investigational mRNA-based seasonal influenza vaccine, the company communicated with the FDA on a revised proposal to seek approval and the federal agency will review the product. The vaccine's PDUFA decision date is August 5, 2026.
18.02.2026 14:26 — 👍 1 🔁 0 💬 0 📌 0
Eric Hall, PhD, MPH, led a modeling study around delaying the universal birth dose hepatitis B vaccine, and he offered some insights of potential healthcare costs when moving away from hepatitis B vaccine birth dose.
www.contagionlive.com/view/the-hum...
A newly proposed federal insurance rule for 2027 omits long-promised protections on copay assistance, allowing insurers and pharmacy benefit managers (PBMs) to continue diverting billions of dollars intended to help patients afford prescription drugs.
16.02.2026 20:05 — 👍 0 🔁 0 💬 0 📌 0
A real-world population study from Spain shows that universal infant immunization with Beyfortus significantly reduced RSV-related hospitalizations not only in the first RSV season, but also into the second year of life.
16.02.2026 15:01 — 👍 1 🔁 0 💬 0 📌 3
A 6-year study in Liberia shows that Lassa fever is frequently missed in febrile patients, leading to preventable deaths and underscoring the urgent need for earlier diagnosis and improved testing. #IDsky #Medsky
15.02.2026 15:48 — 👍 1 🔁 0 💬 0 📌 1
This week, listen in on commentary around the potential removal of the COVID-19 vaccine from the US market, read about FDA's refusal to review Moderna's influenza vaccine, CDC's investigation on invasive E coli, and more.
www.contagionlive.com/view/top-inf...
